S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
S&P 500   4,374.90 (-1.54%)
DOW   34,454.17 (-1.19%)
QQQ   361.93 (-2.27%)
AAPL   142.72 (-1.82%)
MSFT   286.38 (-2.65%)
FB   343.17 (-2.94%)
GOOGL   2,731.75 (-3.18%)
TSLA   775.64 (-1.99%)
AMZN   3,324.00 (-2.40%)
NVDA   209.27 (-3.38%)
BABA   152.61 (+1.62%)
NIO   35.18 (-4.32%)
CGC   14.28 (-2.92%)
GE   106.10 (+0.71%)
MU   74.09 (-1.45%)
AMD   102.71 (-5.04%)
T   27.26 (-0.51%)
F   14.38 (+1.55%)
ACB   6.88 (+7.67%)
DIS   175.65 (-1.46%)
PFE   43.05 (-1.19%)
BA   219.57 (-2.05%)
AMC   37.65 (-4.20%)
NASDAQ:VCNX

Vaccinex Stock Forecast, Price & News

$2.16
-0.08 (-3.57 %)
(As of 09/28/2021 02:07 PM ET)
Add
Compare
Today's Range
$2.13
$2.17
50-Day Range
$2.16
$2.55
52-Week Range
$1.63
$9.56
Volume502 shs
Average Volume2.10 million shs
Market Capitalization$66.53 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
30 days | 90 days | 365 days | Advanced Chart
Receive VCNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.


Vaccinex logo

About Vaccinex

Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in April 2001 and is headquartered in Rochester, NY.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCNX
CIK
N/A
Employees
40
Year Founded
N/A

Sales & Book Value

Annual Sales
$630,000.00
Book Value
($0.12) per share

Profitability

Net Income
$-28,850,000.00

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$66.53 million
Next Earnings Date
11/12/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.13 out of 5 stars

Medical Sector

1181st out of 1,353 stocks

Pharmaceutical Preparations Industry

573rd out of 666 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Vaccinex (NASDAQ:VCNX) Frequently Asked Questions

What stocks does MarketBeat like better than Vaccinex?

Wall Street analysts have given Vaccinex a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vaccinex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Vaccinex?

Vaccinex saw a decrease in short interest in the month of August. As of August 13th, there was short interest totaling 714,900 shares, a decrease of 20.8% from the July 29th total of 902,100 shares. Based on an average daily volume of 417,500 shares, the days-to-cover ratio is currently 1.7 days. Approximately 5.2% of the company's shares are short sold.
View Vaccinex's Short Interest
.

When is Vaccinex's next earnings date?

Vaccinex is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Vaccinex
.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings data on Monday, August, 16th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.08.
View Vaccinex's earnings history
.

How has Vaccinex's stock price been impacted by COVID-19?

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VCNX shares have decreased by 48.2% and is now trading at $2.16.
View which stocks have been most impacted by COVID-19
.

Who are Vaccinex's key executives?

Vaccinex's management team includes the following people:
  • Maurice Zauderer, President, Chief Executive Officer & Director
  • Elizabeth Evans, Chief Operating Officer
  • Scott E. Royer, Chief Financial & Accounting Officer
  • Ernie Smith, Chief Scientific Officer & Senior VP-Research
  • John E. Leonard, Senior Vice President-Development

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.11%), Point72 Asset Management L.P. (1.39%), Telemetry Investments L.L.C. (0.42%), Geode Capital Management LLC (0.37%), State Street Corp (0.24%) and Simplex Trading LLC (0.00%). Company insiders that own Vaccinex stock include Albert Friedberg and Maurice Zauderer.
View institutional ownership trends for Vaccinex
.

Which institutional investors are selling Vaccinex stock?

VCNX stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for Vaccinex
or view top insider-selling stocks.

Which institutional investors are buying Vaccinex stock?

VCNX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Vanguard Group Inc., State Street Corp, Simplex Trading LLC, Geode Capital Management LLC, Virtu Financial LLC, Telemetry Investments L.L.C., and HAP Trading LLC. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg, and Maurice Zauderer.
View insider buying and selling activity for Vaccinex
or or view top insider-buying stocks.

How do I buy shares of Vaccinex?

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $2.16.

How much money does Vaccinex make?

Vaccinex has a market capitalization of $66.53 million and generates $630,000.00 in revenue each year.

How many employees does Vaccinex have?

Vaccinex employs 40 workers across the globe.

What is Vaccinex's official website?

The official website for Vaccinex is www.vaccinex.com.

Where are Vaccinex's headquarters?

Vaccinex is headquartered at 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at (585) 271-2700 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.